Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
China · Delayed Price · Currency is CNY 94.46
-1.86 (-1.93%)
May 8, 2026, 3:00 PM CST
SHA:688578 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,672 | 5,187 | 3,558 | 2,018 | 790.94 | 530.08 |
Other Revenue | 0.24 | 0.24 | 0.04 | 0.06 | 0.06 | 0.02 |
| 5,673 | 5,187 | 3,558 | 2,018 | 791 | 530.09 | |
Revenue Growth (YoY) | 44.95% | 45.80% | 76.29% | 155.14% | 49.22% | 94409.97% |
Cost of Revenue | 209.38 | 164.58 | 143.49 | 77.87 | 47.11 | 29.95 |
Gross Profit | 5,463 | 5,023 | 3,414 | 1,940 | 743.9 | 500.14 |
Selling, General & Admin | 2,380 | 2,243 | 1,578 | 1,052 | 524.11 | 366.44 |
Research & Development | 435.33 | 413.37 | 314.49 | 313.06 | 175.71 | 200.61 |
Other Operating Expenses | 77.27 | 69.22 | 46.81 | 26.6 | 5.11 | 2.79 |
Operating Expenses | 2,892 | 2,726 | 1,940 | 1,392 | 705.26 | 569.95 |
Operating Income | 2,571 | 2,297 | 1,475 | 548.3 | 38.64 | -69.81 |
Interest Expense | -0.13 | -0.13 | -0.07 | -0.16 | -0.33 | -0.61 |
Interest & Investment Income | 74.41 | 68.18 | 67.04 | 60.19 | 33.06 | 30.06 |
Currency Exchange Gain (Loss) | -5.66 | -5.66 | 1.9 | 4.35 | 17.17 | -3.38 |
Other Non Operating Income (Expenses) | -3.26 | -0.92 | 0.17 | 0.99 | -1.06 | -0.43 |
EBT Excluding Unusual Items | 2,636 | 2,359 | 1,544 | 613.68 | 87.47 | -44.16 |
Gain (Loss) on Sale of Investments | 35.81 | 40.29 | 28.89 | 22.67 | 32.36 | 48.13 |
Gain (Loss) on Sale of Assets | -2.55 | -2.53 | -0.01 | -0.02 | -1.68 | -0.57 |
Other Unusual Items | 140.92 | 148.65 | 45.66 | 19.89 | 7.85 | 14.88 |
Pretax Income | 2,811 | 2,545 | 1,619 | 656.22 | 126 | 18.27 |
Income Tax Expense | 395.98 | 355.83 | 188.67 | 12.05 | -4.52 | - |
Net Income | 2,415 | 2,189 | 1,430 | 644.17 | 130.52 | 18.27 |
Net Income to Common | 2,415 | 2,189 | 1,430 | 644.17 | 130.52 | 18.27 |
Net Income Growth | 57.38% | 53.10% | 121.97% | 393.54% | 614.22% | - |
Shares Outstanding (Basic) | 450 | 450 | 450 | 450 | 450 | 457 |
Shares Outstanding (Diluted) | 450 | 450 | 450 | 450 | 450 | 457 |
Shares Change (YoY) | 0.12% | 0.18% | -0.18% | 0.09% | -1.49% | 23.59% |
EPS (Basic) | 5.36 | 4.86 | 3.18 | 1.43 | 0.29 | 0.04 |
EPS (Diluted) | 5.36 | 4.86 | 3.18 | 1.43 | 0.29 | 0.04 |
EPS Growth | 57.19% | 52.83% | 122.38% | 393.10% | 625.00% | - |
Free Cash Flow | 2,347 | 2,137 | 1,296 | 606.77 | -52.21 | -162.95 |
Free Cash Flow Per Share | 5.21 | 4.74 | 2.88 | 1.35 | -0.12 | -0.36 |
Dividend Per Share | 1.000 | 1.000 | 0.650 | 0.400 | - | - |
Dividend Growth | 53.85% | 53.85% | 62.50% | - | - | - |
Gross Margin | 96.31% | 96.83% | 95.97% | 96.14% | 94.05% | 94.35% |
Operating Margin | 45.32% | 44.28% | 41.45% | 27.17% | 4.88% | -13.17% |
Profit Margin | 42.57% | 42.20% | 40.19% | 31.92% | 16.50% | 3.45% |
Free Cash Flow Margin | 41.38% | 41.19% | 36.42% | 30.06% | -6.60% | -30.74% |
EBITDA | 2,611 | 2,336 | 1,511 | 585.25 | 58.8 | -56 |
EBITDA Margin | 46.03% | 45.04% | 42.48% | 29.00% | 7.43% | -10.56% |
D&A For EBITDA | 40.02 | 39.28 | 36.32 | 36.94 | 20.16 | 13.81 |
EBIT | 2,571 | 2,297 | 1,475 | 548.3 | 38.64 | -69.81 |
EBIT Margin | 45.32% | 44.28% | 41.45% | 27.17% | 4.88% | -13.17% |
Effective Tax Rate | 14.09% | 13.98% | 11.66% | 1.84% | - | - |
Revenue as Reported | 5,673 | 5,187 | 3,558 | 2,018 | 791 | 530.09 |
Advertising Expenses | - | - | - | - | 201.38 | 22.44 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.